Questions about SSRI antidepressant drug regulation [1]

Lancet

Volumn 364, Issue 9434, 2004, Pages 577-

  Hay, Alastair ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

CLINICAL RESEARCH; DEPRESSION; DRUG APPROVAL; DRUG RESEARCH; HUMAN; LETTER; MENTAL INSTABILITY; PRIORITY JOURNAL; SUICIDE ATTEMPT; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CANADA; DEPRESSIVE DISORDER; DISCLOSURE; DRUG INDUSTRY; GREAT BRITAIN; HUMANS; SEROTONIN UPTAKE INHIBITORS; SUICIDE; UNITED STATES;

EID: 4143136762     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16838-4     Document Type: Letter

References (2)

1. The Lancet. Is GSK guilty of fraud? Lancet 2004; 363: 1919.
2. Stewart H. Glaxo changes tack after Spitzer assault. http://www.guardian. co.uk/business/story/0,,1242494,00.html (accessed July 27, 2004)